{"filing":{"accession_number":"0001193125-26-302539","cik":"0000860730","ticker":"HCA","company_name":"HCA Healthcare, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"hca-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/860730/000119312526302539/hca-20260714.htm"},"events":[{"id":17741,"run_id":15906,"accession_number":"0001193125-26-302539","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"HCA Healthcare issued a press release on July 14, 2026 announcing preliminary financial results for Q2 2026, including revenues of $20.230 billion, net income of $1.699 billion ($7.62 per diluted share), and Adjusted EBITDA of $4.027 billion, along with revised 2026 full-year guidance.","company_name":"HCA Healthcare, Inc.","ticker":"HCA","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16329,"accession_number":"0001193125-26-302539","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"HCA Healthcare issued a press release on July 14, 2026 announcing preliminary financial results for Q2 2026, including revenues of $20.230 billion, net income of $1.699 billion ($7.62 per diluted share), and Adjusted EBITDA of $4.027 billion. The filing also includes revised 2026 full-year guidance with adjusted revenue, net income, and EPS ranges. This is a classic earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:41:48.943468+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16330,"accession_number":"0001193125-26-302539","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"HCA Healthcare issued a press release on July 14, 2026 announcing preliminary financial and operating results for Q2 2026, including revenues of $20.230 billion, net income of $1.699 billion ($7.62 per diluted share), and Adjusted EBITDA of $4.027 billion. The filing also includes revised 2026 full-year guidance with adjusted revenue, net income, and EPS ranges. This is a classic earnings release disclosure under Item 7.01 (Regulation FD Disclosure), furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:41:48.943468+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16329,"accession_number":"0001193125-26-302539","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"HCA Healthcare issued a press release on July 14, 2026 announcing preliminary financial results for Q2 2026, including revenues of $20.230 billion, net income of $1.699 billion ($7.62 per diluted share), and Adjusted EBITDA of $4.027 billion. The filing also includes revised 2026 full-year guidance with adjusted revenue, net income, and EPS ranges. This is a classic earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:41:48.943468+00:00","company_name":"HCA Healthcare, Inc.","ticker":"HCA","filing_date":"2026-07-14"},{"id":16330,"accession_number":"0001193125-26-302539","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"HCA Healthcare issued a press release on July 14, 2026 announcing preliminary financial and operating results for Q2 2026, including revenues of $20.230 billion, net income of $1.699 billion ($7.62 per diluted share), and Adjusted EBITDA of $4.027 billion. The filing also includes revised 2026 full-year guidance with adjusted revenue, net income, and EPS ranges. This is a classic earnings release disclosure under Item 7.01 (Regulation FD Disclosure), furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:41:48.943468+00:00","company_name":"HCA Healthcare, Inc.","ticker":"HCA","filing_date":"2026-07-14"}]}